Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: John Patterson who wrote (446)	5/12/1999 4:11:00 PM
From: Biomaven	Respond to of 712

John, I guess you get to experience the downside of letting doctors at all these fancy new drugs. <g> When I blithely said "bleeding hasn't been a problem" I was of course speaking purely with my investment hat on. For the patient with bleeding following these drugs (and thus for doctors like you) it sure is a problem. Given that you are much closer to these issues than the rest of us, what is your explanation for the present dominance of ReoPro vs. Integrillin? I would assume it is some combination of a first mover advantage, the excellent long-term mortality studies of ReoPro when used with stents, and maybe the problems Integrillin had with the advisory committee. I think the key ReoPro studies that are now happening are those where it is used in combo with Retavase - these would expand its market, but not really at the expense of Integrillin. What do you see happening with Integrillin in terms of market adoption? Peter